Suven Life Sciences Share Price

The company release the financial statements for the second quarter of the financial year spanning 2018-2019 and the unaudited standalone results indicate:

The total income of the company over the course of the quarter was Rs.96.10 crore.

The total expenses incurred by the company over the course of the quarter was pegged at Rs.71.25 crore.

The net profit for the quarter was pegged at Rs.18.00 crore.

The basic and diluted earnings per share of the company was pegged at Rs.1.41.

Q1 Results FY19

The company released the unaudited standalone financial statement for the results of the first quarter of the financial year FY19 and the results indicate:

1. The total income of the company was Rs.199.78 crore.
2. The total expenses incurred by the company over the quarter was pegged at Rs.140.00 crore.

1. The net profit for the period was calculated to be Rs.38.84 crore.
2. The basic and diluted earnings per share by the close of the first quarter was Rs.3.05.

Annual Report FY 2017-2018

From the audited annual report of the company indicating the standalone financial results, we can see the following:

1. The revenue from operations earned by the company over the course of FY17 was Rs.544.47 crore. By the end of FY18, it had grown to Rs.625.25 crore.

1. The total income of the company for FY17 was Rs.565.57 crore. This was lower than the total income of the company for FY18 at Rs.648.52 crore.
2. The total expenses incurred by the company over the course of the financial year was calculated to be Rs.418.26 crore. This was an increase from the previous year when the total expense was calculated to be Rs.406.21 crore.
3. The net profit for the FY18 was Rs.158.42 crore while it was Rs.123.47 crore in FY17.
4. While the basic and diluted earnings per share for FY17 was Rs.9.69, it was Rs.12.43 for FY18.

Q4 Results FY18

The company released the audited standalone financial results for the final quarter of the financial year spanning 2017-2018 with the year ending in March 2018. The results indicated the following:

1. The total income of the company over the the course of the quarter was Rs.222.94 crore. This was an increase over the total income of the previous quarter, pegged at Rs.166.94 crore.
2. The total expenses incurred by the company over the course of the quarter was Rs.129.09 crore. The total expenses incurred by the company over the course of the previous quarter was Rs.118.83 crore.
3. The net profit for the quarter was Rs.62.51 crore. This was an increase from the profit for the previous quarter which was clocked at Rs.34.59 crore.
4. The basic and diluted earnings per share was Rs.4.90 while it was Rs.2.72 in the previous quarter.

Stock trends in 2018

1. In January 2018, the stock was trading at about Rs.204 per share. The stock fluctuated a bit over the course of the month, even spiking at one point but closed for the month at about Rs.215.
2. The price of the stock declined over the course of February 2018. An interim 150% dividend was announced on 6 February 2018. The price of the stock declined and the final price for the month was about Rs.187.
3. The price of the stock declined further in March 2018 with the final price for the month being about Rs.167.
4. The stock began gaining some ground in April 2018 with the final price for the month being about Rs.179.

1. The price of the stock increased further in May 2018 and the final price for the month was about Rs.191.
2. The price of the stock peaked in mid-June and then decreased over the course of the rest of the month. The final price for June 2018 was about Rs.207.
3. The price of the stock did increase over the course of July 2018 with the stock breaching the Rs.200 mark. The final price for the month was close to Rs.230.
4. The price of the stock visibly increased over the course of the month of August 2018 with the final price for the month being about Rs.279.
5. The stock went over Rs.300 per share in the month of September 2018 but it did not sustain this price for a long time. The stock then fell in price to close for the month at about Rs.269.

1. The decline of the price of the shares continued into October 2018 and the final price for that month was about Rs.241.
2. There was a brief increase in prices in November 2018 but the final price for the month was about Rs.241.
3. The price declined even more in December 2018 and the final price for the month was about Rs.226.

Stock trends in 2017

1. The price of the shares were a little over Rs.170 per share in the beginning of January 2017. The stock fluctuated a bit but the magnitude of change in prices was not much. This continued into February 2017. An interim 100% dividend was announced on 8 February 2017 and the stock price declined after that. The stock did not recover from the downward trend till the end of March 2017.

1. April 2017 marked a period of increase in the prices of the shares of the company and this was sustained till May. The stock did fluctuate a lot but it always regained the higher prices. June 2017 marked a period during which the stock dipped in price again. The final price for June 2017 was about Rs.171.
2. In July 2017, the stock dipped even more in price with August 2017 reflecting the lowest points. The stock slowly gained over the course of September that year and the stock peaked at some point over the course of the third week of the month. Then the stock declined in price again but the decline was not much. The final price for September was about Rs.177.
3. In October 2017, the stock rose in price again and declined over the course of November. The stock continued on a decline till mid-December and then gained a little. The final price for December 2017 was about Rs.203.

Stock trends in 2016

1. The stock was trading at about Rs.164 in the beginning of the year. The months of January and February 2016 saw a decline in prices with the stock appearing to gain a little in the last couple of days of trading in February 2016. The stock remained steady till about the final week of March 2016. A special 100% dividend was announced on 14 March 2016.

1. The stock appeared to be going on a downward path in April 2016 but recovered. The stock remained steady throughout the month of May 2016. After the first week of June 2016, the stock began declining in price. The stock did gain a little towards the end of the month and the final price was about Rs.206.
2. The stock remained steady in price throughout July 2016 and most of August 2016. The stock declined in price over the course of the last week of the month and gained a bit in September. The final price for September was about Rs.200.
3. The stock declined in price over the course of October. November, and December in 2016. The final price for December 2016 was about Rs.172.

Should you invest in stocks of Suven Life Sciences?

1. The company is at the forefront of its industry.

1. The company has received a number of awards for its work. This indicates quality work.
2. The company has locations around the world.
3. The company has generally reported strong earnings and shows some level of profit potential.
4. The company had more than 410 patents lined up for March 2018. This shows a strong culture of innovation. It also shows that the company has a strong earning potential.

Considering all of this, the stocks of the company may be a good buy. But this should be done only after careful research since stocks are highly volatile.

Company information

The company has received the "Best under A Billion" award from Forbes. The company has four business segments—contract research and manufacturing services (CRAMS), drug discovery and development support services (DDDSS), drug discovery and research or clinical pipeline, and formulation development. The company has a separate headquarters in New Jersey in USA.

History of the company

The company was initially promoted as a private limited company in the year 1989. Mr. and Mrs. Venkat Jasti were the promoters. The company began operations in the year 1990. In 1991, the company ventured into the fine chemical intermediates industry. This proved so successful that the company also ventured into export of the same. It was not until the month of January in the year 1995 that the company was converted into a public limited company. Once this was done, the stocks of the company were available on the BSE and NSE. In the year 1997, the company achieved ISO 9002 Certification. Eventually, the company developed a state-of-the-art research and development centre. This was given due recognition by the Ministry of Science and Technology in the Government of India. Eventually, the company set up world class facilities for manufacturing pharmaceuticals. In the year 2003, the company was renamed to Suven Life Sciences Limited. During this year, the company also acquired the assets of an American company called Synthon Chiragenics Corporation. From this point onwards, the company went from a position of strength to strength and continued to dominate its industry.

Management

The individuals heading the Board of the company are:

Mr. Venkat Jasti - Chairman and CEO

Dr. M.R. Naidu - Director

Smt. Sudharani Jasti - Wholetime Director

Mr. D.G. Prasad - Director

Prof. Seyed E. Hasnain - Director

Mr. M. Gopalakrishna - Director

Mr. Santanu Mukherjee - Director

Smt. J.A.S. Padmaja - Director

Suven Life Sciences listings on NSE, BSE and other stock indices

The company is listed on the BSE and NSE under the following codes:

1. BSE: 530239
2. NSE: SUVENEQ
3. IND: Pharmaceuticals
4. ISIN Code: INE495B01038
5. SECT: Pharmaceuticals and health care

The company is part of the following indices:

1. Nifty 500
2. Nifty MidSmallcap 400
3. Nifty Smallcap 250

1. S&P BSE 250 SmallCap Index
2. S&P BSE 400 MidSmallCap Index
3. S&P BSE 500
4. S&P BSE AllCap
5. S&P BSE Healthcare

1. S&P BSE MidSmallCap
2. S&P BSE SmallCap

Location

The corporate office of the company is located at the following address:

Suven Life Sciences Limited, Sixth Floor, SDE Serene Chambers, Avenue - 7, Road Number 5, Banjara Hills, Hyderabad - 500 034, Telangana, India

Telephone: +91 40 2354 1142 / +91 40 2354 3311

Fax: +91 40 2354 1152

Stocks vs. Mutual Funds: here's what we recommend

Stock market investments require a lot of research and knowledge. They do not generally offer any tax benefits and are regarded as high-risk investments. Hence,it is crucial to have a diversified portfolio. At Bankbazaar, we encourage our readers to invest on mutual funds.It doesn't require a lot of knowledge and equity linked mutual fund schemes offer tax benefits. Additionally, since mutual funds comprise stocks from multiple companies, they help in building a diversified portfolio.

DISCLAIMER:

The contents of this post/blog does not constitute financial or other professional advice nor does it imply in any manner a principal-agent relationship, and is not a professional advice on a specific financial matter.